NCT04653480招募中2 期
Surufatinib and Toripalimab Combined With Chemotherapy for Second-line Treatment of Advanced RAS/BRAF Mutant and Microsatellite Stable Colorectal Cancer
Zhejiang University1 个研究点 分布在 1 个国家目标入组 61 人开始时间: 2021年2月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 61
- 试验地点
- 1
- 主要终点
- Overall Response Rate
研究概览
简要总结
To determine the efficacy and safety of surufatinib, toripalimab and chemotherapy in second-line RAS/BRAF mutant and MSS colorectal cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years, ≤75 years
- •Histologically confirmed colorectal cancer with distant metastasis.
- •Progression on first line therapy
- •RAS/BRAF mutant and microsatellite stable
- •Patients can swallow pills normally
- •Expected overall survival ≥6 months
- •Blood routine: no blood transfusion or blood products usage within 14 days, G-CSF or other hematopoietic stimulator was not used. WBC counts > 3000/µl，Absolute neutrophil count (ANC) ≥ 1500 cells/µl，Platelet count ≥ 100,000/µl，Hemoglobin ≥ 9.0 g/dL.
- •AST, ALT and alkaline phosphatase ≤ 2.5 times the upper limit of normal (ULN)，Serum bilirubin ≤ 1.5 x ULN，creatinine<ULN
- •Prothrombin time (PT), international standard ratio (INR) ≤1.5 × ULN
- •Patients who have not received immunotherapy
- •Women of childbearing age must be willing to use adequate contraceptives during the study period of drug treatment;
- •Informed consent has been signed.
排除标准
- •Patients have received ≥2 line systemic therapy;
- •Active bleeding within 3 months; Occurrence of arterial/venous thrombosis within 6 months; Hereditary or acquired bleeding (e.g., clotting dysfunction) or thrombotic tendencies; Full dose oral or injectable anticoagulants or thrombolytic drugs for therapeutic purposes are currently being used or have been used recently (10 days prior to the commencement of study treatment); Surgery (except for biopsy) was performed within 4 weeks prior to the study or the surgical incision was not fully healed; Aspirin (> 325 mg/ day) or dipyridamole, ticlopidine, clopidogrel, and silotazole are currently being used or have recently been used (10 days prior to the study).
- •Systemic corticosteroids or other systemic immunosuppressive drugs were used within 2 weeks prior to treatment. Immunosuppressive drugs were started or expected to be used during the trial. Inhaled corticosteroids, physiologic replacement doses of glucocorticoids are allowed.
- •Certain or suspected brain metastases.
- •The patient has a history of autoimmune disease.
- •Serious uncontrolled systemic diseases, such as severe active infections;
- •A person is known to be infected with the immunodeficiency virus (HIV) or known to be HIV-positive;
- •Patients have suffered from other malignancies in the past 5 years except cervical carcinoma in situ or basal cell carcinoma of the skin
- •Untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers (HBV DNA >500 IU/mL) or active HCV carriers with HCV RNA can be detected. Remarks: Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B patients (HBV DNA < 500 IU/mL) may be enrolled
- •Anti-infective therapy was not discontinued 14 days before the study;
- •A prior history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia, and symptomatic interstitial lung disease or the presence of active pneumonia on a chest CT scan within 4 weeks prior to the study.
- •Patients have a history of intestinal obstruction within six months. Patients with incomplete obstruction syndrome of ileus at the time of initial diagnosis may be enrolled in the study if they have received definitive (surgical) treatment to resolve the symptoms, as assessed by the investigator.
- •Patients Have high blood pressure that cannot be well controlled by antihypertensive medication (systolic ≥140 mmHg or diastolic ≥90 mmHg)
- •Urine routine indicated urinary protein ≥++ and confirmed 24-hour urinary protein >1.0g;
- •Known to be allergic to any study drug;
- •Patients have participated in other drug clinical studies within 4 weeks before enrollment;
- •Lactating women
- •According to the judgment of the researcher, the patient may have other factors that may affect the results of the study or cause the study to be terminated, such as alcohol abuse, drug abuse, other serious diseases (including mental diseases) requiring combined treatment. Patients have severe laboratory abnormalities, which will affect the safety of the patient.
研究组 & 干预措施
Surufatinib, Toripalimab and Chemotherapy
Experimental
Second line CRC patients received surufatinib 250mg po qd , toripalimab 3mg/kg ivgtt q2w and chemotherapy according to the first line treatment, until disease progression or intolerable toxicity
干预措施: Surufatinib (Drug)
Surufatinib, Toripalimab and Chemotherapy
Experimental
Second line CRC patients received surufatinib 250mg po qd , toripalimab 3mg/kg ivgtt q2w and chemotherapy according to the first line treatment, until disease progression or intolerable toxicity
干预措施: Toripalimab (Drug)
Surufatinib, Toripalimab and Chemotherapy
Experimental
Second line CRC patients received surufatinib 250mg po qd , toripalimab 3mg/kg ivgtt q2w and chemotherapy according to the first line treatment, until disease progression or intolerable toxicity
干预措施: chemotherapy (Drug)
结局指标
主要结局
Overall Response Rate
时间窗: 2 months
the proportion of patients in a trial whose tumor is destroyed or significantly reduced by a drug. ORR is generally defined as the sum of complete responses (CRs) - patients with no detectable evidence of a tumor over a specified time period - and partial responses (PRs) - patients with a decrease in tumor size over a specified time period.
次要结局
- Overall Survival(2 years)
- Progression Free Survival(6 months)
研究者
Weijia Fang, MD
Director of Medical Oncology
Zhejiang University
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung CancerSmall Cell Lung CarcinomaNCT04996771Sun Yat-sen University88
进行中（未招募）
2 期
Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNon Small Cell Lung CancerNCT05003037Li Zhang, MD106
Unknown
2 期
Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLCNon Small Cell Lung CancerNCT02037997Fudan University80
尚未招募
1 期
Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung CancerSmall Cell Lung CancerNCT05882630Fujian Cancer Hospital39
Unknown
不适用
Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung CancerSCLC, Extensive StageLung CancerSmall Cell Lung CancerNCT04731909Third Military Medical University80